6529 POSTER 14-3-3s and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (pts) with EGFR mutations

S.Fernanda; J.L.Ramírez; N.Reguart; R.Porta; M.Provencio; F.Cardenal; M.Cuello; P.Lianes; M.Taron; R.Rosell

首页> 外文期刊>European Journal of Cancer Supplements >6529 POSTER 14-3-3s and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (pts) with EGFR mutations

【24h】

6529 POSTER 14-3-3s and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (pts) with EGFR mutations

机译：厄洛替尼治疗的非小细胞肺癌（NSCLC）EGFR突变患者的血清中6529 POSTER 14-3-3s和带有叉头和无名指（CHFR）甲基化的检查点

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共1页
作者
S.Fernanda; J.L.Ramírez; N.Reguart; R.Porta; M.Provencio; F.Cardenal; M.Cuello; P.Lianes; M.Taron; R.Rosell;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 6528 POSTER Role of ERCC1, XRCC3, Aurora A and TGFBR1 gene single nucleotide polymorphisms (SNP) and CHFR and 14-3-3s methylation in a customized cisplatin (cis) trial based on ERCC1 mRNA levels in stage IV non-small-cell lung cancer (NSCLC) patients (pts) [J] . M.Taron, M.Cobo, L.Isla, European Journal of Cancer Supplements . 2007,第4期

机译：6528在基于IV期非小细胞肺的ERCC1 mRNA水平的定制顺铂（cis）试验中，ERCC1，XRCC3，Aurora A和TGFBR1基因单核苷酸多态性（SNP）和CHFR和14-3-3s甲基化的作用癌症（NSCLC）患者（pts）
2. 6530 POSTER High correspondence between EGFR mutations in tissue and in circulating DNA form non-small-cell lung cancer (NSCLC) patients (pts) with poor performance status (PS) [J] . M.Clara, T.Moran, L.Paz-Ares, European Journal of Cancer Supplements . 2007,第4期

机译：6530 POSTER表现状态（PS）不良的非小细胞肺癌（NSCLC）患者（pt）的组织和循环DNA中的EGFR突变之间的高度对应
3. Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations. [J] . Taron M Clinical cancer research: an official journal of the American Association for Cancer Research . 2011,第5期

机译：厄洛替尼治疗的EGFR突变晚期非小细胞肺癌患者的治疗前EGFR T790M突变和BRCA1 mRNA表达。
4. Diagnosis of lymph node metastasis in non-small-cell lung cancer (NSCLC) patient on F-18-FDG PET/CT [C] . Tsu-Chi Cheng, Nan-Tsing Chiu, Ting-Yu Su, International Forum on Medical Imaging in Asia 2019 . 2019

机译：F-18-FDG PET / CT诊断非小细胞肺癌（NSCLC）淋巴结转移
5. Use of Palliative Radiotherapy Among Metastatic Non-small-cell Lung Cancer (NSCLC) Patients in Puerto Rico [D] . ?Quinones Avila, Valerie 2020

机译：在波多黎各的转移性非小细胞肺癌（NSCLC）患者中使用姑息放射治疗
6. Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations [O] . Mo Tang, Shumei Wang, Bin Zhao, 2019

机译：中药可延长表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗的非小细胞肺癌（NSCLC）携带EGFR突变的患者的无进展生存期并增强治疗效果
7. P2-092: 14-3-3 sigma and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations [O] . Reguart Noemi, Porta Rut, Cantos Blanca, 2007

机译：P2-092：厄洛替尼治疗的具有EGFR突变的非小细胞肺癌（NSCLC）患者（p）的血清中叉状和无名指（CHFR）甲基化为14-3-3 sigma和检查点

6529 POSTER 14-3-3s and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (pts) with EGFR mutations

著录项

相似文献

相关主题

期刊订阅